| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02357225 | Pompe Disease | Drug: Pyridostigmine Bromide | University of Florida | Early Phase 1 | 2015-08-01 | 2016-10-25 |
| NCT01415921 | Heart Failure | Drug: Pyridostigmine Bromide | New York University School of Medicine|Nathan Kline Institute for Psychiatric Research|Oklahoma State University|National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 2011-10-01 | 2016-08-31 |
| NCT00276406 | Constipation|Diabetes Mellitus|Colonic Transit|Gastric Emptying | Drug: Pyridostigmine|Drug: Placebo | Mayo Clinic|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Center for Research Resources (NCRR) | Phase 1|Phase 2 | 2006-05-01 | 2012-11-02 |
| NCT01993680 | Autonomic Disturbances in Parkinson`s Disease | Drug: Pyridostigmine bromide|Drug: fludrocortisone | University of Zurich | Phase 2 | 2012-06-01 | 2015-09-29 |
| NCT02941328 | Spinal Muscular Atrophy|SMA|Kugelberg-Welander Disease | Drug: Pyridostigmine|Drug: Placebo | UMC Utrecht | Phase 2 | 2015-12-01 | 2016-10-19 |
| NCT00953914 | Diabetes Complications | Drug: Pyridostigmine|Drug: Placebo | Hospital de Clinicas de Porto Alegre | | 2005-03-01 | 2011-07-06 |
| NCT02307526 | Hypotension, Postural | Drug: Pyridostigmine Bromide | James J. Peters Veterans Affairs Medical Center | Phase 2 | 2011-01-01 | 2014-12-01 |
| NCT02157545 | Muscle Relaxants | | Shashi Bhatt, MD|University of Toledo Health Science Campus | Phase 4 | 2014-03-01 | 2016-07-15 |
| NCT01370512 | Orthostatic Hypotension | Drug: Droxidopa|Drug: Pyridostigmine Bromide | Mayo Clinic | Phase 2 | 2011-11-01 | 2016-09-12 |
| NCT00518154 | HIV Infections | Drug: Pyridostigmine tablets | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 2 | 2007-09-01 | 2009-04-16 |
| NCT02227823 | Spinal Muscular Atrophy Type 3 | Drug: Pyridostigmine Bromide | Centre Hospitalier Rgional de la Citadelle | Phase 2 | 2014-07-01 | 2014-08-26 |
| NCT02364180 | Muscle Weakness | | University of Toledo Health Science Campus | Phase 3 | 2013-12-01 | 2016-02-02 |
| NCT00409435 | Postural Tachycardia Syndrome | Drug: pyridostigmine|Drug: Placebo | Mayo Clinic|National Institutes of Health (NIH) | | 2006-10-01 | 2017-03-21 |
| NCT00535587 | Fibromyalgia | Behavioral: Exercise|Drug: pyridostigmine|Drug: Placibo|Behavioral: Attention Control | Oregon Health and Science University|National Institute of Nursing Research (NINR) | Phase 2 | 2002-09-01 | 2011-03-23 |
| NCT02850276 | HIV Disease | Drug: Pyridostigmine | Icahn School of Medicine at Mount Sinai|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Early Phase 1 | 2015-11-01 | 2016-07-27 |
| NCT03063515 | Diabetes Mellitus | Drug: Pyridostigmine | University of Miami|American Diabetes Association | Phase 1 | 2017-03-01 | 2017-02-21 |
| NCT02308124 | Orthostatic; Hypotension, Neurogenic | Drug: Midodrine|Drug: Pyridostigmine Bromide|Drug: Midodrine + pyridostigmine bromide | Seoul National University Hospital | Phase 4 | 2014-11-01 | 2015-04-15 |
| NCT02893553 | Spinal Cord Injury|Autonomic Dysreflexia|Baroreceptor Integrity|Sympathetic Integrity|Vagal Integrity|Autonomic Integrity|Hypotensive|Cognitive Function|Cerebral Blood Flow|Blood Pressure | Drug: Midodrine Hydrochloride|Drug: Pyridostigmine Bromide|Drug: Mirabegron|Other: Placebo | James J. Peters Veterans Affairs Medical Center|Kessler Foundation | Phase 2 | 2016-12-01 | 2016-12-27 |
| NCT02171988 | Postural Orthostatic Tachycardia Syndrome | Drug: Propranolol|Drug: Bisoprolol|Drug: Propranolol+pyridostigmine|Drug: Bisoprolol+pyridostgmine | Seoul National University Hospital | Phase 4 | 2014-03-01 | 2016-04-14 |
